JO2931B1 - Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway - Google Patents

Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway

Info

Publication number
JO2931B1
JO2931B1 JO2010188A JOP20100188A JO2931B1 JO 2931 B1 JO2931 B1 JO 2931B1 JO 2010188 A JO2010188 A JO 2010188A JO P20100188 A JOP20100188 A JO P20100188A JO 2931 B1 JO2931 B1 JO 2931B1
Authority
JO
Jordan
Prior art keywords
pathway antagonists
hedgehog pathway
disubstituted phthalazine
phthalazine hedgehog
disubstituted
Prior art date
Application number
JO2010188A
Other languages
Arabic (ar)
English (en)
Inventor
كومار باتل بارفين
ويلسوم تاكاكو ( ني تكاكوا)
ارثر هيبسكسيند فيليب
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2931B1 publication Critical patent/JO2931B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JO2010188A 2009-06-19 2010-06-10 Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway JO2931B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
JO2931B1 true JO2931B1 (en) 2015-09-15

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2010188A JO2931B1 (en) 2009-06-19 2010-06-10 Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway

Country Status (35)

Country Link
US (2) US8273742B2 (OSRAM)
EP (1) EP2443104B1 (OSRAM)
JP (1) JP5596139B2 (OSRAM)
KR (1) KR101389165B1 (OSRAM)
CN (1) CN102459233B (OSRAM)
AR (1) AR077014A1 (OSRAM)
AU (1) AU2010260244B2 (OSRAM)
BR (1) BRPI1011601A2 (OSRAM)
CA (1) CA2764542C (OSRAM)
CL (1) CL2011003147A1 (OSRAM)
CO (1) CO6480932A2 (OSRAM)
CR (1) CR20110658A (OSRAM)
DK (1) DK2443104T3 (OSRAM)
DO (1) DOP2011000386A (OSRAM)
EA (1) EA019059B1 (OSRAM)
EC (1) ECSP11011541A (OSRAM)
ES (1) ES2409054T3 (OSRAM)
HN (1) HN2011003139A (OSRAM)
HR (1) HRP20130408T1 (OSRAM)
IL (1) IL216599A (OSRAM)
JO (1) JO2931B1 (OSRAM)
MA (1) MA33363B1 (OSRAM)
MX (1) MX2011014029A (OSRAM)
MY (1) MY156667A (OSRAM)
NZ (1) NZ596882A (OSRAM)
PE (1) PE20121050A1 (OSRAM)
PL (1) PL2443104T3 (OSRAM)
PT (1) PT2443104E (OSRAM)
SG (1) SG177289A1 (OSRAM)
SI (1) SI2443104T1 (OSRAM)
TN (1) TN2011000627A1 (OSRAM)
TW (1) TWI385165B (OSRAM)
UA (1) UA106755C2 (OSRAM)
WO (1) WO2010147917A1 (OSRAM)
ZA (1) ZA201108587B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201071248A1 (ru) * 2008-04-29 2011-06-30 Эли Лилли Энд Компани Дизамещенные фталазиновые антагонисты пути hedgehog
HRP20130527T1 (en) * 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
CA2743264C (en) * 2008-11-17 2014-02-18 Julia Marie Clay Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
EP3303289A4 (en) * 2015-06-05 2018-11-14 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
WO2021261601A1 (ja) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
JP2023546536A (ja) * 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (OSRAM) * 1977-06-03 1981-03-07 Pfizer
JP4169368B2 (ja) 1996-01-15 2008-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脈管形成阻害性ピリダジンアミン
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
DE60016402T2 (de) 1999-06-08 2005-10-27 Lorantis Ltd. Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
JP4658473B2 (ja) * 2001-07-27 2011-03-23 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
EP1496905B1 (en) * 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
CN1984904A (zh) 2004-05-08 2007-06-20 神经能质公司 3－芳基－5,6－二取代哒嗪
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
AU2008269128B2 (en) * 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
EA017918B1 (ru) * 2007-12-13 2013-04-30 СИЕНА БИОТЕК С.п.А. Антагонисты пути hedgehog и их терапевтические применения
EA201071248A1 (ru) * 2008-04-29 2011-06-30 Эли Лилли Энд Компани Дизамещенные фталазиновые антагонисты пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
HRP20130527T1 (en) 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
CA2743264C (en) 2008-11-17 2014-02-18 Julia Marie Clay Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
TN2011000627A1 (en) 2013-05-24
CO6480932A2 (es) 2012-07-16
CL2011003147A1 (es) 2012-07-20
US9000023B2 (en) 2015-04-07
KR101389165B1 (ko) 2014-04-24
ES2409054T3 (es) 2013-06-24
AU2010260244B2 (en) 2013-09-05
AU2010260244A1 (en) 2012-01-19
WO2010147917A1 (en) 2010-12-23
CN102459233A (zh) 2012-05-16
DK2443104T3 (da) 2013-05-06
EP2443104B1 (en) 2013-04-17
MA33363B1 (fr) 2012-06-01
NZ596882A (en) 2013-08-30
HRP20130408T1 (en) 2013-06-30
EP2443104A1 (en) 2012-04-25
AR077014A1 (es) 2011-07-27
SG177289A1 (en) 2012-02-28
KR20120024783A (ko) 2012-03-14
HN2011003139A (es) 2013-07-29
PL2443104T3 (pl) 2013-08-30
US8273742B2 (en) 2012-09-25
EA019059B1 (ru) 2013-12-30
ECSP11011541A (es) 2012-01-31
SI2443104T1 (sl) 2013-07-31
IL216599A0 (en) 2012-03-01
JP5596139B2 (ja) 2014-09-24
TW201113268A (en) 2011-04-16
PE20121050A1 (es) 2012-08-09
DOP2011000386A (es) 2012-02-29
MY156667A (en) 2016-03-15
BRPI1011601A2 (pt) 2016-03-22
CN102459233B (zh) 2014-07-02
US20120316174A1 (en) 2012-12-13
EA201270049A1 (ru) 2012-05-30
JP2012530705A (ja) 2012-12-06
CA2764542C (en) 2013-09-10
US20100324048A1 (en) 2010-12-23
HK1164872A1 (en) 2012-09-28
IL216599A (en) 2015-09-24
CR20110658A (es) 2012-02-20
CA2764542A1 (en) 2010-12-23
MX2011014029A (es) 2012-02-21
TWI385165B (zh) 2013-02-11
PT2443104E (pt) 2013-05-07
ZA201108587B (en) 2013-05-29
UA106755C2 (uk) 2014-10-10

Similar Documents

Publication Publication Date Title
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
EA201171367A1 (ru) Винилиндазолильные соединения
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2011007930A (es) Conjugados de insulina cristalina.
IN2012DN03883A (OSRAM)
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MY186456A (en) Quinazoline carboxamide azetidines
IN2012DN02471A (OSRAM)
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
CY1114078T1 (el) Ανταγωνιστες διυποκατεστημενης φθαλαζινης του μονοπατιου hedgehog
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
UA36741U (ru) 1-фенил-4-о-толиламино-1,5-дигидропиррол-2-он, который проявляет анальгетическую и противовоспалительную активность
TN2010000583A1 (en) Organic compounds
UA43993U (en) S-derivatives of 5-r-4-r1-1,2,4-triazole-3-thione exhibiting anti-inflammatory activity
UA106224C2 (en) Crystalline insulin-conjugates